ALK and non-small cell lung carcinoma: Based on the results of the phase I/II clinical trials, brigatinib (at a dose of 180 mg once daily with a 7-day lead-in period at 90 mg once daily) was compared to crizotinib in the first-line setting in 275 ALK-positive NSCLC patients in the phase 3 ALTA- 1L trial.